Search

Displaying results 4201 - 4210 of 10000 in total
  1. Drug

    MCC

    go.drugbank.com/drugs/DB05282
    Investigational

    The product is a sterile biological composition in a sub-micron suspension. It is produced at the Bioniche manufacturing facility in Pointe-Claire, Quebec.

  2. Drug

    Omega-6 fatty acids

    go.drugbank.com/drugs/DB13168
    InvestigationalNutraceutical

    Omega-6 fatty acids are polyunsaturated fatty acids with a final carbon-carbon double bond in the n-6 position, that is, the sixth bond, counting from the methyl end. … Cells involved in the inflammatory response are typically rich in the n-6 fatty acid arachidonic acid, as generally, eicosanoids derived from n-6 PUFA are pro-inflammatory.

    Synonyms: n-6 fatty acids
  3. Drug

    Tarenflurbil

    go.drugbank.com/drugs/DB05289
    Investigational

    It is a selective amyloid lowering agent (SALA) that reduces levels of the toxic peptide amyloid beta 42 (Aβ42) in cultured human cells and in animal models. … Tarenflurbil is an investigational drug that was studied in patients with mild Alzheimer's disease.

  4. Drug

    C326

    go.drugbank.com/drugs/DB06017
    Experimental

    C326 is an investigational compound under investigation in clinical trial NCT00353756 (Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease) for the treatment … The drug is composed of an IL-6–binding trimer and a IgG-binding domain.

  5. Drug

    Aceprometazine

    go.drugbank.com/drugs/DB01615
    Experimental

    Although not widely prescribed, it is used in combination with meprobamate for the treatment of sleep disorders in France under the trade name Mepronizine.

  6. Drug

    Amcinonide

    go.drugbank.com/drugs/DB00288
    Approved

    Amcinonide is a corticosteroid.

  7. Drug

    Giredestrant

    go.drugbank.com/drugs/DB19125
    Investigational

    Giredestrant is under investigation in clinical trial NCT06065748 (A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With Er-positive

  8. Drug

    Etrolizumab

    go.drugbank.com/drugs/DB12189
    Investigational

    [A244574] In the case of [natalizumab], which targets the α4 integrin subunit, this has also resulted in undesirable blockade of lymphocyte CNS trafficking and reported cases of progressive multifocal … Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is typified by a chronic gastrointestinal inflammatory microenvironment, driven in part by the excessive infiltration

  9. Drug

    MBO7133

    go.drugbank.com/drugs/DB04999
    Experimental

    However, araC is only slowly converted to araCTP in the liver or in primary liver tumors due to low levels of an enzyme in the liver that is required for the conversion of araC to araCMP, the first step … in the activation pathway of the drug.

  10. Drug

    EF-022

    go.drugbank.com/drugs/DB17768
    Investigational

    EF-022 is a modified version of vitamin D binding protein macrophage activator, with potential antineoplastic and anti-angiogenic activities.

    Synonyms: EF 022